| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010556914 |
| P356 | DOI | 10.1046/J.1523-1755.1999.00275.X |
| P698 | PubMed publication ID | 9987071 |
| P2093 | author name string | Hori M | |
| Yukio Ando | |||
| Kaneda Y | |||
| Ohno N | |||
| Imai E | |||
| Isaka Y | |||
| Sudo T | |||
| Akagi Y | |||
| Tsujie M | |||
| Border WA | |||
| Noble NA | |||
| P2860 | cites work | Mechanism of activation of the TGF-beta receptor | Q28245861 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | extracellular matrix | Q193825 |
| gene therapy | Q213901 | ||
| glomerulonephritis | Q605006 | ||
| P304 | page(s) | 465-475 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis | |
| P478 | volume | 55 |
| Q45879506 | A realistic chance for gene therapy in the near future |
| Q36019916 | Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria |
| Q41422693 | Association of transforming growth factor-β1 polymorphisms with the risk of chronic kidney diseases |
| Q36350431 | Attenuation of corneal myofibroblast development through nanoparticle-mediated soluble transforming growth factor-β type II receptor (sTGFβRII) gene transfer |
| Q33793187 | Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy |
| Q40658343 | BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells |
| Q37081505 | Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? |
| Q34726861 | Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis |
| Q43072994 | Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). |
| Q33212952 | Effects of drug serum of anti-fibrosis I herbal compound on calcium in hepatic stellate cell and its molecular mechanism |
| Q35883541 | Experimental strategies to reverse chronic renal disease. |
| Q34074844 | Gene therapy for kidney disease |
| Q34808035 | Gene therapy for renal disorders: what are the benefits for the elderly? |
| Q36691191 | Gene therapy targeting kidney diseases: routes and vehicles |
| Q38235004 | Henoch-Schönlein purpura nephritis in children |
| Q35791678 | Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction |
| Q37442681 | Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists |
| Q34983331 | Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. |
| Q42486771 | Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-β1 expression in mesangial cells: biochemical and structural considerations |
| Q35829510 | Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy |
| Q40818094 | Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. |
| Q34382535 | Lentiviral-mediated RNA interference against TGF-beta receptor type II in renal epithelial and fibroblast cell populations in vitro demonstrates regulated renal fibrogenesis that is more efficient than a nonlentiviral vector |
| Q34792580 | Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects |
| Q35888212 | Liposome-mediated gene therapy in the kidney |
| Q45869374 | Modulation of renal glomerular disease using remote delivery of adenoviral‐encoded solubletype II TGF‐β receptor fusion molecule |
| Q38062404 | Molecular targets for treatment of kidney fibrosis |
| Q44051276 | Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity |
| Q45887723 | Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction |
| Q40277998 | Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene |
| Q35533319 | Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters |
| Q35141421 | Renal gene transfer: nonviral approaches |
| Q35170428 | Role of tissue stroma in cancer cell invasion |
| Q44507331 | Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats |
| Q45865268 | Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats |
| Q33804142 | TGF-beta and fibrosis |
| Q58700082 | Targeting TGF-β Signaling in Kidney Fibrosis |
| Q36739752 | Therapeutic potential of TGF-beta inhibition in chronic renal failure |
| Q73626743 | Transforming growth factor-beta receptor-II up-regulation during wound healing in previously irradiated graft beds in vivo |
| Q34389106 | Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease |
| Q44298458 | Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling |
| Q43545284 | Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin |
| Q24683744 | Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-beta signaling in activated T lymphocytes |
Search more.